Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(66.7%)

N/A

2(33.3%)

6Total

Phase 2(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07005414Phase 2Completed

Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models

Role: lead

NCT06911905Phase 2Completed

Efficacy of Nutritional Supplements on Children With Autism Spectrum Disorder

Role: lead

NCT07045584Not ApplicableCompleted

Temporal Pole Transcranial Alternating Current Stimulation for Children With Autism Spectrum Disorder

Role: lead

NCT06700798Phase 2Recruiting

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Role: lead

NCT06476899Phase 2Not Yet Recruiting

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

Role: lead

NCT01832337Not ApplicableUnknown

Limb Remote Ischemic Preconditioning for Heart and Intestinal Protection During Laparoscopic Colorectal Surgery

Role: lead

All 6 trials loaded